Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Monitoring the Immunological Response to Human Cancer

Natural and vaccine-induced immune responses to cancer-testis antigen-derived peptides

Danila Valmori
Danila Valmori
1Ludwig Institute Clinical Trial Center, New York, NY
2Ludwig Institute for Cancer Research, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2003
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The isolation of CD8+ cytolytic T cells (CTL) reactive to the autologous tumors in cancer patients has allowed, during the last decade, the identification of several categories of tumor-associated antigens that can be the target of tumor-specific immune responses. Among them, one of the most relevant for the development of cancer vaccines is the group of the so-called Cancer-Testis (CT) antigens, which are expressed by tumor cells but not by most somatic adult tissues, with the exception of testis. Because of their expression commonly found in tumors of various histological types, CT antigen-derived peptides recognized by tumor reactive CTL are relevant candidates for generic vaccination of cancer patients.

In the last two years, we have analyzed the natural response to four CT antigen-derived HLA-A2 restricted epitopes recognized by tumor reactive CTL. Three of them correspond to the previously described peptides from MAGE-A10 (254-262), NY-ESO-1 (157-165) and CAMEL (1-11). The fourth peptide corresponds to the first identified SSX-2 (41-49) derived epitope, which has recently been defined in our laboratory. For each peptide natural responses were analyzed in circulating lymphocytes of melanoma patients bearing or not antigen expressing tumors, as well as in healthy donors. The results obtained indicate that the repertoire of specific CD8+ T cells available for each of these peptides is composed of T-cell clones able to recognize the antigen with different functional avidity. In each case, avidity of antigen recognition directly correlated with the efficiency of tumor recognition. Both high and low avidity CTL could be isolated from either melanoma patients or healthy donors. However, isolation of high avidity CTL was significantly more frequent from patients bearing antigen-expressing tumors. Natural responses to the four peptides were also found among tumor infiltrating lymphocytes (TIL) and tumor infiltrated lymph node cells (TILN) from some patients bearing tumor lesions expressing the corresponding antigens. Interestingly, in each case, specific CTL isolated from TIL or TILN displayed high avidity of antigen recognition and tumor reactivity. These results indicate that both high and low avidity CTL specific for the analyzed peptides are a normal constituent of the repertoire of CD8+ T cell available for these antigens and that high avidity, tumor-reactive CTL are selectively expanded during spontaneous immune responses to antigen expressing tumors.

On the basis of these results, clinical trials of cancer patient's vaccination with CT antigen- derived peptides have recently being undertaken with the aim of either inducing or boosting natural tumor-specific immune responses. In a trial that in currently ongoing at the Ludwig Institute Clinical Trial Center (New York Branch at Division of Medical Oncology, Columbia University, New York), we analyzed the CD8+ T-cell response to a NY-ESO-1 peptide vaccine in three sarcoma patients bearing NY-ESO-1 expressing lesions and with no specific immune response detectable prior to vaccination. The vaccine consisted of the 9-mer NY-ESO-1 157-165 and the 11-mer 157-167 administered together with granulocyte-macrophage colony-stimulating factor (GM-CSF) as systemic adjuvant. Consistent with the results of previous studies, we detected, in these patients, a significant CD8+ T-cell response to the vaccine. By analyzing this response more in detail, however, we found that the largest part of the vaccine elicited CD8+ T cells were directed against multiple distinct epitopes in the 157-167 region and were non tumor reactive. Only a minor fraction of elicited CD8+ T cells directed against the 9-mer 157-165, and of sufficient high functional avidity, recognized the naturally processed target on NY-ESO-1+ tumor cells. In a separate study conducted at the Division of Clinical Onco-immunology of the Ludwig Institute for Cancer Research, (Lausanne Branch, Switzerland), a single patient with metastatic ocular melanoma received vaccination with four melanoma antigen derived peptides, including the 9-mer NY-ESO-1 157-165, administered with Montanide. Peptide NY-ESO-1 157-165 was remarkably immunogenic in this formulation and induced a CD8+ T-cell response detectable ex vivo at an early time point of the immunization protocol. The vaccine-induced CD8+ T-cell response decreased upon dismissed peptide administration, but was boosted by further peptide injections. Importantly, vaccine-elicited CD8+ T cells specifically lysed NY-ESO-1 expressing tumor cells. Together, the results of these studies underline that, because of the complexity of the repertoire of CD8+ T cells that can be elicited by vaccination with synthetic peptides, a precise definition of the targeted epitope and, hence, of the corresponding peptide to be used as immunogen, is required to ensure a precise targeting of the tumor.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2003 by Danila Valmori
PreviousNext
Back to top
Cancer Immunity Archive: 3 (Suppl 1)
January 2003
Volume 3, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Natural and vaccine-induced immune responses to cancer-testis antigen-derived peptides
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Natural and vaccine-induced immune responses to cancer-testis antigen-derived peptides
Danila Valmori
Cancer Immun January 1 2003 (3) (Suppl 1) 16;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Natural and vaccine-induced immune responses to cancer-testis antigen-derived peptides
Danila Valmori
Cancer Immun January 1 2003 (3) (Suppl 1) 16;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1
  • Monitoring of immune responses against NY-ESO-1 in cancer patients
  • Comprehensive approaches to monitor CD8+ T-cell responses against tumor antigen NY-ESO-1
Show more Monitoring the Immunological Response to Human Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement